Use of 18F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma

Surgery

Volumn 144, Issue 5, 2008, Pages 793-802

  Makino, Tomoki ^a   Doki, Yuichiro ^a   Miyata, Hiroshi ^a   Yasuda, Takushi ^b   Yamasaki, Makoto ^a   Fujiwara, Yoshiyuki ^a   Takiguchi, Shuji ^a   Higuchi, Ichiro ^a   Hatazawa, Jun ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LUNG DISEASE; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENT LARYNGEAL NERVE PALSY; RETROSPECTIVE STUDY; SAMPLE; THERAPY EFFECT; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 53949111150     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.06.026     Document Type: Article

References (46)

1. Girvin G.W., Matsumoto G.H., Bates D.M., et al. Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. Am J Surg 169 (1995) 557-559
2. Urschel J.D., and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185 (2003) 538-543
3. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
4. Doki Y., and Ishikawa O. Takachi k, et al. Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg 29 (2005) 700-707
5. Matsuyama J., Doki Y., Yasuda T., et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141 (2007) 570-580
6. Kijima F., Natsugoe S., Takao S., et al. Detection and clinical significance of lymph node micrometastasis determined by reverse transcription-polymerase chain reaction in patients with esophageal carcinoma. Oncology 58 (2000) 38-44
7. Kato H., Kuwano H., Nakajima M., et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94 (2002) 921-928
8. Kobori O., Kirihara Y., Kosaka N., and Hara T. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 86 (1999) 1638-1648
9. Yoon Y.C., Lee K.S., Shim Y.M., et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 227 (2003) 764-770
10. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
11. Choi J.Y., Lee K.H., Shim Y.M., et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 41 (2000) 808-815
12. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
13. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
14. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
15. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
16. Takayama N., Arima S., Haraoka S., et al. Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res 23 (2003) 4435-4442
17. Aiko S., Yoshizumi Y., Ishizuka T., et al. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Dis Esophagus 20 (2007) 94-101
18. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8 (2005) 393-406
19. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
20. Sobin L.H., and Wittekind C. TNM classification of malignant tumors. 6th ed. (2002), John Wiley and Sons, Inc, New York
21. Yano M., Takachi K., Doki Y., et al. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 19 (2006) 158-163
22. Akita H., Doki Y., Miyata H., et al. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 93 (2006) 401-409
23. The National Cancer Center Institute Common Toxicity Criteria version 2.0
24. Miyata H., Yano M., Doki Y., et al. A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol 93 (2006) 477-484
25. Paul A.K., Tatsumi M., Higuchi I., et al. Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun 24 (2003) 963-970
26. Tatsumi M., Yutani K., Watanabe Y., et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 40 (1999) 566-573
27. Fukunaga H., Sekimoto M., Tatsumi M., et al. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer. Int J Oncol 20 (2002) 691-695
28. Dittler H.J., Fink U., and Siewert G.R. Response to chemotherapy in esophageal cancer. Endoscopy 26 (1994) 769-771
29. Jones D.R., Parker Jr. L.A., Detterbeck F.C., and Egan T.M. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85 (1999) 1026-1032
30. Jager P.L., Que T.H., Vaalburg W., et al. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. Eur J Nucl Med 28 (2001) 1845-1849
31. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18 (2000) 3202-3210
32. Ando N., Iizuka T., Ide H., et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21 (2003) 4592-4596
33. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
34. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
35. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
36. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8 (1997) 963-968
37. Heinmoller E., Renke B., Beyser K., et al. Piffalls in diagnostic molecular pathology-significance of sampling error. Virchows Arch 439 (2001) 504-511
38. Lahdesmaki H., Hao X., Sun B., et al. Distinguishing key biological pathways between primary breast cancers and their lymph node metastases by gene function-based clustering analysis. Int J Oncol 24 (2004) 1589-1596
39. Matheus R.S., Bernardi Fdel C., Gallo C.P., et al. Nuclear markers (star volume, mitotic index, AgNOR and Ki-67) of the primary tumor and its metastasis in non-small cell lung carcinomas. Pathol Res Pract 200 (2004) 13-23
40. Ferrari S., Bertoni F., Zanella L., et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100 (2004) 1936-1942
41. Ajani J.A., Fodor M.B., Tjulandin S.A., et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23 (2005) 5660-5667
42. Yoshioka T., Sakayori M., Kato S., et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 11 (2006) 454-460
43. Armanios M., Xu R., Forastiere A.A., et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 4495-4499
44. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36 (2005) 69-76
45. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106 (2006) 552-558
46. Siewert J.R., and Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?. Semin Radiat Oncol 17 (2007) 38-44